A 64-year-old man from Quebec became the recipient of North America’s first regenerated liver transplant on Thursday, August 13, 2026. The procedure, performed in a Quebec hospital, marks the inaugural use of a lab‑grown organ to replace a failing liver in a human patient on the continent.
The regenerated liver was created using cutting‑edge tissue‑engineering techniques that grow functional liver tissue from a patient’s own cells. Surgeons removed the diseased organ and implanted the lab‑grown graft, completing the operation without the need for a traditional donor organ. The patient’s postoperative monitoring will determine how the new organ integrates and functions over the coming weeks.
Researchers say the breakthrough could add dozens of viable livers to the transplant pool within the technology’s first year of use. By generating organs from a patient’s own cells, the method aims to reduce reliance on scarce donor supplies and eliminate the risk of immune rejection that often accompanies conventional transplants.
The development arrives at a time when North America continues to grapple with a chronic shortage of donor livers, leaving many patients on waiting lists for years. Health officials have long emphasized the need for alternative solutions, and regenerative medicine has been identified as a promising avenue. This successful transplant demonstrates that engineered organs can move from experimental labs to clinical reality, offering a potential new source of life‑saving tissue for thousands of patients awaiting liver replacement.